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The importance of oral cancer 
screening is widely documented in 
the literature.1 Oral cancer preva-
lence continues to increase every 
year, with an estimated 41,380 
new oral cancer cases in 2013.2 
Over 7,890 of those cases are ex-
pected to include a negative prog-
nosis or death from the disease.2 In 
the U.S. alone there are 275,193 
cases living with oral cancer, and 
the average 5 year survival rate 
for those people is 62.2%.2 Late 
detection of oral cancer (when the 
cancer has reached stage III or IV) 
is a contributing factor in high mor-
bidity and mortality rates.3 Several 
factors contribute to the late de-
tection of cancerous lesions such 
as not conducting a comprehensive 
intraoral and extraoral oral cancer 
screening and the difficulty to de-
tect early precancerous and can-
cerous lesions. Because of the diffi-
culty in oral cancer early detection, 
lesions are often detected in ad-
vanced stages and show evidence 
of invasion and metastasis, which 
results in disfigurement from inva-
sive treatments. Late diagnosis of 
the disease is unfortunate because 
oral cancer patients have an 80 
to 90% survival rate when lesions 
are detected early (premalignant 
lesions, or when the lesion is on 
stage I) (Table I).2 Early diagnosis 
of oral cancer results in minimal-
ly invasive procedures and better 
prognosis.4 Premalignant lesions, 
stage I and II oral cancers can re-
main undetected until symptoms 
present clinically.4,5 According to 
the National Cancer Institute, the 
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Abstract
Purpose: This study compared the effectiveness of the VELscope® 
Vx versus visual and tactile intraoral examination in detecting oral 
lesions in an adult, high risk population.
Methods: The pilot study compared the intra oral findings be-
tween 2 examination types. The sample was comprised of 30 par-
ticipants who were addicted to either cigarettes or a dual addic-
tion (cigarettes plus hookah). High risk population was defined as 
males who were current cigarette smokers or had a dual addiction. 
Two trained and experienced licensed dental hygienists conducted 
all examinations. Throughout the study, all visual and tactile in-
traoral examinations were conducted first by one dental hygienist 
first, followed by the VELscope® Vx fluorescence examinations by 
the second dental hygienist. All subjects received an inspection 
of the lips, labial and buccal mucosa, floor of the mouth, dorsal, 
ventral and lateral sides of the tongue, hard and soft palate, and 
visual inspection of the oropharynx and uvula. Both evaluations 
took place in 1 visit in the Dental Hygiene Research Center at Old 
Dominion University and external sites. All participants received 
oral cancer screening information, recommendations, referrals for 
tobacco cessation programs and brochures on the 2 types of ex-
aminations conducted.
Results: Participants were considered high risk based on demo-
graphics (current smokers and mostly males). Neither visual and 
tactile intraoral examination nor the VELscope® Vx examination 
showed positive lesions. No lesions were detected; therefore, no 
referrals were made. Data indicated the duration of tobacco use 
was significantly higher in cigarette smokers (14.1 years) than 
dual addiction smokers (5 years) (p>0.005). The average num-
bers of cigarettes smoked per day were 13.5 compared to 14.2 
cigarettes for dual addiction smokers.
Conclusion: Results from this study suggest the visual and tactile 
intraoral examination produced comparative results to the VEL-
scope® Vx examination. Findings from this study support that the 
VELscope® Vx is still considered an adjunct technology and cannot 
be used exclusively for oral cancer screening.
Keywords: oral cancer, VELscope® Vx, dual addiction, oral poten-
tially malignant lesions
This study supports the NDHRA priority area, Clinical Dental Hy-
giene Care: Investigate how dental hygienists use emerging sci-
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highest survival rate in early cancerous lesions 
is for stage I lip cancer (96.3%), whereas the 
lowest survival rate is for stage II tongue cancer 
(58.6%).5 According to Healthy People 2020, de-
tecting oral and pharyngeal cancers at the earli-
est stages (stage I and II) is a critical objective.6 
In 2007, 32.5% of the oral and pharyngeal can-
cers detected were at their earliest stages.6 This 
suggests that by the year 2020 the percentage of 
oral and pharyngeal cancers diagnosed at early 
stages should reach a 10% improvement.6 Since 
oral cancer is mostly detected in late stages, al-
most one-half of oral cancer survivors are at risk 
of developing local or regional recurrence and/
or distant metastasis.7 In addition, up to 90% 
of treatment failures are for local and regional 
recurrences.7
Early cancer or premalignant lesions can mim-
ic benign lesions, appearing as asymptomatic, 
white lesions (Leukoplakia) or red lesions (Eryth-
roplakia). The surgical removal of leukoplakia is 
only obligatory when the dysplasia is diagnosed 
as moderate to severe. On the other hand, eryth-
roplakia transforms to squamous cell carcinoma 
or carcinoma in situ in 90% of the cases. How-
ever, some of the red and white lesions do not 
always progress into malignant lesions.3,5 Safe, 
cost effective technologies could improve diag-
nosis and early treatment, and would decrease 
mortality rates while minimizing disfigurement.4 
Research shows long-term effects of late diag-
nosis, including aggressive treatments and dis-
figurement, xerostomia, chewing and swallowing 
difficulties, dental caries, and depression.1 Cur-
rently, the only accurate differential diagnosis is 
through scalpel biopsy and histologic examina-
tion which are gold standard diagnosing proce-
dures but severely invasive and expensive.3
Intraoral and extraoral visual and tactile exam-
ination is still the standard of care for oral can-
cer screening. Traditional oral cancer screening 
includes taking an updated medical and dental 
history to identify risk factors including tobacco 
use (smoking or smokeless), alcohol consump-
tion, HPV infection, frequent exposure to ultravi-
olet light, poor nutrition and genetic factors.8 The 
National Institute of Dental and Craniofacial Re-
search developed an oral cancer screening pro-
tocol for the clinicians to use with every patient 
as a part of the regular periodic appointment.8 
The examination consists of 2 parts: extraoral 
examination, intraoral soft tissue examination. 
The extraoral examination includes visual and 
palpatory inspection of the face, ears, neck and 
the regional lymph nodes areas. Comprehensive 
intraoral soft tissue examination requires a visual 
and palpatory evaluation of the lips, labial mu-
cosa, right and left buccal mucosa, gingiva, the 
dorsal, ventral and lateral sides of the tongue, 
the floor of the mouth, the hard and soft palate, 
and the oropharynx and uvula. Practicing dental 
hygienists and dentists are using mixed oral can-
cer screening protocols or none at all.8 There is 
little guidance for dental hygienists or dentists 
who are interested in improving their oral can-
cer detection because of the lack of standard-
ization regarding the benefits of traditional oral 
cancer screenings versus optical or technology-
based imaging in early detection of oral cancer. 
The similarity in appearance between benign and 
premalignant oral lesions makes it difficult to rely 
on the traditional oral cancer screening.
The Oral Cancer Foundation supports research 
and development of technology-based techniques 
and devices that are non-invasive to detect initial, 
asymptomatic cell change as soon as possible.9 
Technology-based devices capabilities include in-
creased ability by oral health care professionals 
to identify, contrast (abnormal versus abnormal), 
and monitor submucosal and dysplastic changes 
not visible during a visual oral cancer screening. 
While these screening devices do not differenti-
ate between malignant and benign lesions, when 
used in conjunction with a traditional oral cancer 
screening, they may assist oral health profes-
sionals in recognizing abnormal lesions or oral 
potentially malignant lesions at earlier stages.1
Oral cancer screening tools such as the VEL-
Site
Stage
I II III IV
Lip 96.3% 82.7% 56.7% 48.1%
Tongue 70.7% 58.6% 47.3% 36.7%
Floor of the mouth 72.5% 60.1% 35.8% 29.7%
Gingiva and other 
soft tissue 80.9% 62.2% 45.1% 40.0%
Table I: Five-Year Oral Cancer Relative Survival Rate, Based on the Data from the Na-
tional Cancer Institute, SEER Program, NIH
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scope® Vx, LED (Dental Inc, Burnaby, BC, Can-
ada); Identafi® (StarDental, Lancaster, PA); 
ViziLite® Plus with TBlue, ZILATM (Fort Collins, 
Colo.); and the MicroluxTM/DL, (AdDental Inc, 
Danbury, Conn.), are technology-based devices 
available for use in private practice and public 
health settings (Table II). Technology-based de-
vices include hand-held operating systems that 
use several chemiluminescence, blue-white LED 
and autofluorescence to penetrate epithelial tis-
sue; light based systems enhance the visual in-
spection of intraoral tissues and help distinguish 
healthy areas versus oral potentially malignant 
lesions occurring at the submucosal layers and 
therefore not readily visible to the naked eye. 
Each device has individual defining features 
aimed to detect submucosal cell change or rapid 
destructive cell mutation and determine whether 
the lesion has metastasized to underlying con-
nective tissue. This is a limitation of visual oral 
cancer screening examinations. More research is 
needed to support the use of technology-based 
screening tools for early detection of oral cancer 
in the general (low-risk) populations.10-13 Also, 
current literature does not support exclusive use 
of technology-based screening protocols in re-
ducing mortality rates in smokers.12
VELscope® Vx is a non-magnifying, wide-field 
imaging device. The original VELscope® was pri-
marily approved by the FDA on April, 2006 to 
be used as an adjunct oral mucosal examination 
device. In November 2010, the newer genera-
tion VELscope® Vx was 
approved by the FDA 
for the same purposes 
(Figure 1).14 The new 
VELscope® Vx is easi-
er to carry, allows for 
broader intramural im-
aging and is cordless 
(utilizing a 12 hour 
battery). It does not 
require a dimmed light 
and can be used un-
der incandescent light. 
VELscope® Vx has a 
higher intensity for a 
better visualization; 
an external camera at-
tachment was added 
to facilitate a photo 
documentation of sus-
picious lesions during 
exams. Researchers 
choose the new gen-
eration VELscope Vx 
because of these ad-
vances in the tech-
nology and to provide 
research on the most 
current device.
The Identafi® system 
uses 3 light modes: 
a white light mode, a 
Product Name Company Dispensing Method Unique Features
VELscope® Vx LED Dental Inc.
• Lighted device 
• Emits blue-light 
• Clinician views oral cavity through 
the VELscope® Vx lens
• Cordless, portable 
• Digital camera attachment 
• Uses blue light to simulate natural 
fluorescence 
• No solutions used
Identafi® DentalEZ groupStarDental
• Hand-held mirror emits 3 differ-
ent type of light modes 
• Safe blue light, white light and 
amber light into the oral cavity 
• Clinician views tissue discolor-
ation using the three modes
• Cordless, portable 
• Ability to examine tissue vascula-
ture 





• Uses low energy blue-white light 
source 
• Clinician activates the light source 
by bending the vial container then 
insert it to a holder
• Cordless, portable 
• Requires, with Microlux/DL, a 
pre-rinse for 30 seconds 
• Can be used in conjunction with 
TBlue (Tuludine blue-based dye)
MicroluxTM/DL AdDentIncorporated
• Produces blue-white LED light 
source 
• Clinician views white lesions
• Cordless, portable device 
• Requires, with ViziLite® Plus, a 
pre-rinse for 60 seconds
Table II: Oral Cancer Screening Devices
Figure 1: Visual En-
hanced Lesion Scope 
(VELscope® Vx)
Source: picture provided by 
LED dental Inc., the manu-
facturer of the VELscope® Vx
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fluorescent violet mode and an amber reflectance 
mode. Identafi® fluorescent light makes an ab-
normal lesion appear dark brown or black, and 
healthy tissue reflect as blue fluorescence areas. 
ViziLite® Plus with TBlue system uses a low en-
ergy blue white light source, which requires a 30 
second acetic acid pre-rinse that dehydrates the 
tissue. Normal tissue appears healthy pink, while 
abnormal tissue appears as acetowhite in color.
MicroluxTM/DL system uses a blue-white LED 
light source. It uses a bright light, illumination 
technology, but is currently recognized specifi-
cally for better discovery of keratotic lesions that 
might not be discovered using the chair-side 
light. Abnormal tissue will appear as acetowhite, 
while normal tissue will appear as a healthy pink 
in color. The VELscope® Vx elicits a green, homo-
geneous fluorescence of normal tissue (Figure 2). 
A reduction in the green fluorescence indicates 
abnormal tissue.15 However, the abnormality may 
indicate either pathological conditions (such as 
precancerous or cancerous lesions) or variation 
from normal structures (such as Linea alba in the 
buccal mucosa).
Unlike other types of light-based systems, the 
VELscope® Vx does not require a pre-rinse and 
does not contain a lesion-marking solution. The 
VELscope® Vx allows for the adaptation of a digi-
tal camera, which aids in monitoring and access-
ing submucosal parameters of suspicious lesions. 
In addition to the recommendations from the 
Oral Cancer Foundation,9 Marzouki et al16 con-
cluded that “the VELscope may add sensitivity to 
the clinical examination and be a useful adjunct 
in high-risk patients.”
Under the VELscope® Vx light dysplastic and 
malignant cells will appear as a dark area of ab-
normality as they interrupt and cause a loss of 
fluorescence.13 Preliminary studies showed that 
the sensitivity and specificity of the VELscope® 
Vx were both higher than 90%.10,11,16 The evi-
dence support the effectiveness of the VELscope® 
Vx in identifying extended borders of known le-
sions but there is not enough evidence to support 
or refute its effectiveness in detecting early oral 
cancer lesions in general populations.10,11
VELscope® Vx and other screening devices 
have high false positive rates.10 The positive and 
negative predictive values of the VELscope® Vx 
were found to be around 42 and 98%, respec-
tively.3,16 For the Vizilite® Plus with TBlue, the 
sensitivity was found to be a median of 85%, the 
median specificity was 67%. The positive predic-
tive value was 85% and the negative predictive 
value was 83%.3 Therefore, the literature recom-
mend the use of these devices may be useful as 
opportunistic screening protocol with high risk 
populations, where the pretest probability of oral 
cancer is above 10%.10
This study supports the need for more re-
search using new technologies. According to a 
systematic review conducted by Kujan et al, no 
evidence exists to suggest that other methods 
of screening, toluidine blue, fluorescence imag-
ing or brush biopsy, are effective as a diagnos-
tic tool.10,12 VELscope® Vx is of particular interest 
because there are limited studies examining the 
effectiveness of the VELscope® Vx as an oral can-
cer screening tool in high risk populations. Unlike 
other technologies, the device has minimal con-
traindications; per manufacturer’s instructions, 
individuals taking medications that cause photo-
sensitivity or predisposed to photosensitivity are 
contraindicated for use of the VELscope® Vx be-
cause of the blue-white fluorescent light emitted 
by the device.10
High risk populations include those who smoke 
tobacco - smoking has been firmly established 
as a direct causal link to oral cancer.17 The risk 
of oral and oropharyngeal cancer increases with 
regular alcohol consumption.17 The Healthy Peo-
ple 2020 report identified tobacco and alcohol 
consumption as priorities for the prevention of 
cancer.6 According to the American Cancer So-
ciety, 7 out of 10 oral cancer patients are heavy 
drinkers.18 Since tobacco is one of the most com-
mon modifiable known risk factor of oral cancer, 
cigarette smokers were chosen in this study as 
the target population.
Figure 2: Tissue Appearance under the 
Velscope® Vx
Source: Photographs used by permission. Taken at the 
Dental Hygiene Research Center, Old Dominion University.
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Results
Thirty participants with a mean age of 42 years 
were enrolled. Seventeen participants were ciga-
rettes smokers and 13 participants reported dual 
addiction (Table III). Cigarette smokers consisted 
of 76.5% males (n=13) and 23.5% females (n=4). 
For the dual addiction smokers, 77% were males 
(n=10) and 23% (n=3) were females. Fifteen par-
ticipants identified their ethnicity as Asian, 10 Cau-
casian, 3 African-American, 1 Hispanic and 1 Na-
tive American (Table III).
In participants who smoked cigarettes, the av-
erage length of time smoking was 14.1 years, 
whereas the average length of time smoking for 
dual addiction smokers was 5 years (Table IV). 
Methods and Materials
A convenience sample of 30 cigarette smokers 
or dual addiction (cigarette and hookah) smok-
ers from the state of Virginia, Hampton Roads 
area (Norfolk, Virginia Beach, and Chesapeake) 
were recruited. Recruitment flyers were distrib-
uted electronically through the university faculty 
and staff email announcement. Recruitment flyers 
were also posted at various locations in the local 
community.
The inclusion criteria included participants 18 
years of age or older and people who smoke ciga-
rettes only or in combination with other type of 
tobacco use (hookah smoking). People who used 
other forms of smoking habits (without cigarette 
smoking) and individuals who were photosensi-
tive were excluded from participation. Data col-
lection took place on the campus of Old Dominion 
University, Norfolk, Virginia and at 3 local senior 
citizens nursing homes. Written informed consent 
was obtained from each participant. Translators 
trained in medical and dental terminology were 
made available to individuals with limited English 
proficiency.
Prior to data collection, the study was approved 
by Old Dominion University institutional review 
board. All participants completed a health infor-
mation and medical history form. Demographic 
data included age, gender and ethnicity/race. The 
health history included questions to determine risk 
for oral cancer to include history of cancer or can-
cer treatments, HPV infection and current medica-
tions. Smoking and alcohol habits were calculated 
according to the frequency of tobacco and alcohol 
use: the number of cigarettes/packs, the number 
of times smoking hookah and the number of alco-
hol drinks consumed were calculated per day, per 
week or per month. The duration of smoking in 
years was also collected. At the completion of the 
study, all participants received recommendations 
regarding tobacco cessation and information on 
the two examinations performed.
Each participant received both a visual and 
tactile intraoral examination and a VELscope® Vx 
examination to assess oral potentially malignant 
lesions. Two licensed dental hygienists served as 
investigators - one investigator conducted the 
visual and tactile intraoral examination and the 
second examiner conducted the VELscope® Vx ex-
amination. The examination sequence was stan-
dardized for all study participants - visual and tac-
tile intraoral examination was conducted first by 
investigator A, while investigator B conducted the 
VELscope® Vx examination second. All investiga-
tors were educated and trained on the use of the 
VELscope® Vx and the interpretation of findings 
by a professional expert from LED Dental Inc, the 
manufacturer of the VELscope® Vx. Investigators 
also viewed a video tutorial on the proper use of 
VELscope® Vx technology and how to interpret 
findings. Because one examiner conducted each 
type of examination, no inter-rater calibration was 
necessary during the study. However, intra-rater 
reliability was measured for each investigator us-
ing test-retest reliability.
Clinical findings were recorded using 6 data col-
lection forms - 3 for visual and tactile intraoral 
examination and 3 for the VELscope® Vx exami-
nation. Examination sequences were standardized 
according to size, shape, color and texture of the 
lesion. The sequence of the visual and tactile in-
traoral examination included bi-digital evaluation 
of the lips, labial mucosa, right and left buccal 
mucosa, visual inspection of the gingiva, bi-digital 
palpation and visual inspection of the dorsal, ven-
tral and lateral sides of the tongue, digital palpa-
tion of the floor of the mouth, visual inspection 
and digital palpation of the hard palate, visual in-
spection of the visible portion of the soft palate, 
and visual inspection of the oropharynx and uvula. 
The VELscope® Vx examination followed the same 
sequence without palpation.
Statistical Analysis
To determine demographic and medical health 
risk behaviors in individuals who smoke tobacco, 
t-test were measured. This test analyzed the sig-
nificant difference between cigarette smokers and 
dual addiction smokers by comparing the number 
of cigarettes smoked per day, number of alcoholic 
drinks consumed per month and length of time 
smoking per year. The significance level was set 
at 0.05.
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Smoking Habit Ethnicity Age Gender
AA A H NA C 19 to 34 >34 Male Female
Cigarette smoking
n=17 2 8 0 0 7 11 6 13 4
Dual Addiction
n=13 1 7 1 1 3 13 0 10 3
Total
n=30 3 15 1 1 10 24 6 23 7
Key: AA=African American; A=Asian; H=Hispanic/Latino; NA=Native American; C=Caucasian
Dual Addiction=Cigarette + hookah smoking
Table III: Demographics
The number of alcohol drinks consumed per month 
for tobacco cigarette smokers was an average of 
5 drinks. For dual addiction smokers, the average 
was 13.9 drinks per month. The number of ciga-
rettes per day for tobacco cigarettes only smokers 
was an average of 13.2 cigarettes, whereas dual 
addiction smokers reported an average of 14.5 cig-
arettes per day (Table IV). Results demonstrated 
a statistically significant difference in the average 
length of time smoking (in years) between the cig-
arettes smokers (14.1 years) and the dual addic-
tion smokers (5 years).
Results showed there was no statistically sig-
nificant difference between cigarette smokers and 
dual addiction smokers in the average number of 
alcoholic drinks per month (5 for cigarette smokers 
and 13.9 for dual addiction). The average number 
of cigarettes smoked per day did not show a statis-
tically significant difference between the 2 groups 
(13.2 for cigarette smokers and 14.5 for dual ad-
diction) (Table IV).
There were no statistically significant differences 
in the oral potentially malignant lesions detected 
in cigarette or dual addiction smokers by the VEL-
scope® Vx when compared to visual and tactile in-
traoral examination. No lesions were identified in 
either group; therefore, results showed no differ-
Smoking 
Habit
Length of Time Smoking 
(Years)
Number of Cigarettes Smoked 
per day
Number of Alcoholic Drinks 
per month




14.1 + 3.11 0.005 13.2 + 2.56 - 5 + 1.79 -
Dual Addiction
n=13 5 + 0.89 0.005 14.5 + 2.92 - 13.9 + 7.63 -
Key: Dual Addiction= Cigarette + hookah smoking
Table IV: Health Determinants
ences between findings in either group. Although 
the study protocol included taking intraoral pho-
tographs and referral to Eastern Virginia Medical 
School for biopsy, no lesions were detected using 
either type of examination; therefore, no intraoral 
photographs or referrals were made.
Discussion
This study was conducted to determine if the 
VELscope® Vx examination lead to improved de-
tection of early stage lesions in submucosal tis-
sues. While results of the 2 examination types 
indicated no statistical difference, the majority 
of participants reported 1 or more high risk be-
haviors for oral cancer. Demographic informa-
tion gathered supports current literature on high 
risk populations and an increase in the number 
of younger populations who become habitual 
smokers and also developing alcohol addiction 
and dual-addiction smoking habits (specifically 
those who smoke both cigarettes and hookah).19 
All participants in this study presented 1 or more 
health risk behaviors, or factors for developing 
potentially malignant oral lesions. 
This pilot study enrolled a small sample size 
and results should be interpreted within that con-
text. Mostly males were enrolled in this study, 
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Conclusion
In this particular study, no lesions were identi-
fied in either group. The absence of findings sup-
ports the need of further high-quality research 
evaluate very carefully the effectiveness of the 
2 tested protocols in identifying the presence of 
oral potentially malignant lesions. This study did 
not produce statistically significant data to sup-
port or refute the use of the Velscope® Vx for 
use as an exclusive oral cancer screening device 
in cigarette smokers or those with dual addic-
tion smoking habits. Therefore, the importance 
of conventional oral cancer screening is still sig-
nificant especially that it includes intraoral and 
extraoral visual and tactile examination of the 
head and neck areas. Then, based on the given 
data, the use of adjunctive technologies, such as 
the VELscope® Vx is kept as the clinician’s choice.
and less than one-third were females.17,20 Al-
though the risk of oral cancer is increasing in 
females, the research suggest overall males ac-
count for the majority of smokers.17 Participants 
who consume alcohol in combination to smoking 
have an added risk of oral cancer; 7 out of 10 
oral cancer patients are heavy drinkers, accord-
ing to the American Cancer Society.18 The litera-
ture identifies black populations as a high risk 
racial group who smoke cigarettes.17,20 In this 
very specific group population, Asians were the 
majority of cigarette and dual addiction smokers.
The outcome of this study may have also been 
influenced by a short observational period. Pa-
tient recruitment efforts were limited to a 3 
month time period, contributing to a small non-
representative sample size of 30 subjects. Both 
examination types were conducted in 1 appoint-
ment. This research study was limited to 1 year; 
this did not allow time for scheduling periodic 
oral cancer screening appointments to observe 
any tissue changes. Limited funding and time 
impeded the development of a cohort study to 
investigate changes or alterations in the oral soft 
tissues throughout a long period of time in high 
risk populations. 
The sample size used in this study was small 
and therefore limited the results. The age range of 
the majority of the sample was between 19 to 34 
years, which indicates a young lower risk popula-
tion. Almost two-thirds of the cigarette smokers 
enrolled were under 34 years old and none of the 
dual addiction smokers were above 34 years old. 
The research identifies adults above 55 years old 
as the highest risk age group.17,20 In this study, 
13 of the 30 participants recorded dual addic-
tion. The literature indicates hookah smoking is 
becoming a trend within adolescents and young 
adults,19 and this study supports that fact.
The lack of concern and education about oral 
cancer may have had an influence on the out-
comes and participation of this study. Research 
suggests that the level of cancer concern ranges 
from low to moderate in general and high risk 
populations.21 There are no consistent findings 
concerning whether cancer worry in high-risk 
populations exceeds that for the general popula-
tion.21 Overall, there is a lack of education on the 
importance of oral cancer screening. Paulis sug-
gests dental hygienists have an important role in 
educating their patients regarding routine com-
prehensive intraoral and extraoral examination 
of the head and neck area for oral cancer early 
detection.22
The VELscope® Vx was initially approved by the 
FDA in 2006 to “enhance the identification and 
visualization of oral mucosal abnormalities that 
may not be apparent or visible to the naked eye, 
such as oral cancer or premalignant dysplasia.”14 
The results of the present study did not show a 
significant difference between the VELscope® Vx 
examination and the visual and tactile intraoral 
examination, thus supporting the importance of 
the thorough traditional intraoral and extraoral 
examination. The lack of the extraoral examina-
tion and the comprehensive palpatory exami-
nation of the head and neck and may have had 
an influence on the outcomes. The VELscope® 
Vx technology is an optical device that is only 
used intraorally; its limitation includes the lack 
of comprehensive soft tissue palpatory examina-
tion. This emphasizes the continued need for a 
thorough traditional visual and palpatory intra-
oral and extraoral examination of the head and 
neck, as well as the thyroid area.
Future studies should include a cohort research 
study design that includes a broader spectrum of 
high risk groups. For example, the inclusion cri-
teria may include individuals having one or more 
oral cancer high risk parameters. Recruitment 
and time needed to conduct the research was 
limited and future studies should also consider 
longitudinal research design. This would allow 
for a greater representation of high risk popu-
lation. To observe the effectiveness of the VEL-
scope® Vx in the detection of the early lesions at 
subclinical levels, the cohort research study de-
sign should include scheduling periodic oral can-
cer screenings of the same participants every 6 
months over a longer period of time that extends 
to several years.
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